一分钟看懂
这是一项关于晚期实体瘤的I 期研究，登记的药物或干预包括IBI3001，当前状态为招募中。登记地点显示中国合肥、北京、福州、南宁等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
IBI3001 · I 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出6项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Affiliated Hospital of Anhui Medical University · 合肥
- Cancer Hospital, Chinese Academy of Medical Sciences · 北京
- Chinese People's Liberation Army General Hospital · 北京
- First Affiliated Hospital, Fujian Medical University · 福州
- Fujian Cancer Hospital · 福州
- The Affiliated Tumor Hospital of Guangxi Medical University · 南宁
- Harbin Medical University Cancer Hospital · 哈尔滨
- Anyang Cancer Hospital · 安阳
- The First Affiliated Hospital of Henan University of Science and Technology · 洛阳
- Henan Cancer Hospital · 郑州
- The First Affiliated Hospital of Zhengzhou University · 郑州
- Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 武汉
- Xiangya Hospital, Central South University · 长沙
- Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University · 南京
- Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University) · 南京
- Jiangxi Cancer Hospital · 南昌
- Shanghai East Hospital, Tongji University School of Medicine · 上海
- Sichuan Cancer Hospital & Institute · 成都
- West China Hospital, Sichuan University · 成都
- The First Affiliated Hospital, Zhejiang University School of Medicine · 杭州
- Zhejiang Cancer Hospital · 杭州
公开的入选条件
- 1. Male or female participants ≥ 18 years old;
- 2. Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
- 3. Has an anticipated life expectancy of ≥ 12 weeks;
- 4. Adequate bone marrow and organ function:
- 5. At least 1 evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. for dose escalation , and 1 measurable lesion for dose expansion.
- 6. Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available; participants who refuse stand
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06349408；登记信息更新于 2026-09-25。